SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

Similar Items

• Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
  od: Bonora, S, i dr.
  Izdano: (2010)
• Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir
  od: Siccardi, Marco, i dr.
  Izdano: (2008)
• Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations
  od: Simiele, Marco, i dr.
  Izdano: (2011)
• Raltegravir Penetration in Seminal Plasma of Healthy Volunteers
  od: Calcagno, Andrea, i dr.
  Izdano: (2010)
• Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
  od: Schipani, Alessandro, i dr.
  Izdano: (2010)